Starpharma Holdings Limited (ASX:SPL)
Australia · Delayed Price · Currency is AUD 0.1250
0.00 (0.00%)
Sep 10, 2025, 10:00 AM AEST
Starpharma Holdings Employees
Starpharma Holdings had 40 employees as of June 30, 2025. The number of employees did not change compared to the previous year.
Employees
40
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
146.25K AUD
Profits / Employee
-249.75K AUD
Market Cap
52.28M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Jun 30, 2025 | 40 | 0 | - |
| Jun 30, 2024 | 40 | -5 | -11.11% |
| Jun 30, 2023 | 45 | -5 | -10.00% |
| Jun 30, 2022 | 50 | 0 | - |
| Jun 30, 2021 | 50 | 5 | 11.11% |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| CSL Limited | 29,904 |
| Pro Medicus | 132 |
| Cochlear | 5,500 |
| Sonic Healthcare | 42,000 |
| Ramsay Health Care | 90,000 |
| Ansell | 15,000 |
| Telix Pharmaceuticals | 234 |
| Mesoblast | 81 |
Starpharma Holdings News
- 2 years ago - Starpharma: Patience Needed, But A Lot To Like - Seeking Alpha
- 3 years ago - Starpharma presents compelling data in Prostate Cancer at ESMO - PRNewsWire
- 3 years ago - Starpharma signs new DEP® agreement with MSD - PRNewsWire
- 4 years ago - Starpharma releases positive DEP® phase 2 interim results in prostate cancer - PRNewsWire
- 4 years ago - US Patent and Trademark Office grants new patent for DEP® cabazitaxel, one of Starpharma's phase 2 clinical-stage cancer treatments - PRNewsWire
- 4 years ago - Stopping Infection: A Missing Link In The Delta Puzzle? Unloved Investment Opportunity In Starpharma - Seeking Alpha
- 4 years ago - Early-Stage Covid Treatment Prospects: Merck/Ridgeback Bio And Starpharma Lead The Pack - Seeking Alpha
- 4 years ago - Starpharma Up With News, Down With None; Timing Entry Makes Sense - Seeking Alpha